A Consideration of the Extent That Tertiary Amines Can Form N-Nitroso Dialkylamines in Pharmaceutical Products
- Ian W. AshworthIan W. AshworthChemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United KingdomMore by Ian W. Ashworth
- ,
- Timothy Curran*Timothy Curran*Email: [email protected]Process Chemistry, Vertex Pharmaceuticals, Inc., Boston, Massachusetts 02210, United StatesMore by Timothy Curran
- ,
- Olivier DiratOlivier DiratRegulatory CMC, Pfizer Global Product Development, Sandwich CT13 9NJ, United KingdomMore by Olivier Dirat
- ,
- Jinjian ZhengJinjian ZhengAnalytical Commercialization Technology, Merck & Co., Inc., Rahway, New Jersey 07065, United StatesMore by Jinjian Zheng
- ,
- Matthew WhitingMatthew WhitingChemical Development, GlaxoSmithKline, Stevenage SG1 2NY, United KingdomMore by Matthew Whiting
- , and
- Daniel LeeDaniel LeeAnalytical Commercialization Technology, Merck & Co., Inc., Rahway, New Jersey 07065, United StatesMore by Daniel Lee
Abstract

Most secondary amines have the potential to undergo nitrosation in the presence of nitrite under certain conditions, particularly at low pH, to generate N-nitrosamines. Tertiary amines are generally considered to be less prone to nitrosamine formation as they require an additional dealkylation step. A review of the published literature combined with recently generated experimental data from nitrosation experiments carried out on several trialkyl amines further informs on the extent that tertiary amines can form N-nitrosamines by reaction with trace levels of nitrite, which may be present during drug substance or drug product manufacture. Simple trialkylamines, amines containing no additional heteroatoms, have been demonstrated to react via a nitrosative dealkylation mechanism that slowly generates a dialkylamine, which in turn nitrosates. This sequence of reactions to generate a N-nitrosamine is approximately 1000-fold slower than the simple nitrosation of a secondary amine of comparable pKa. Therefore, the formation of N-nitrosamines from simple trialkylamines in pharmaceutical products is typically not considered to be a risk. Dialkylanilines are able to access alternative reaction mechanisms and may undergo dealkylative nitrosation with greater ease than simple trialkylamines and therefore require a more focused risk assessment. Finally, certain structurally complex tertiary amines may contain functional groups that can facilitate the formation of N-nitrosamines through resonance and/or inductive electronic effects. Therefore, structures containing highly functionalized tertiary amines require a thorough, compound-specific assessment to determine the level of risk of nitrosamine generation. Note that in situations where higher amounts of nitrosating agents are present, such as when nitrosation chemistry is used during the drug substance manufacturing process, simple trialkylamines should be considered for N-nitrosamine generation during the risk assessment.
Cited By
This article is cited by 1 publications.
- Raphael Nudelman, Grace Kocks, Bruno Mouton, David J. Ponting, Joerg Schlingemann, Stephanie Simon, Graham F. Smith, Andrew Teasdale, Anne-Laure Werner. The Nitrosamine “Saga”: Lessons Learned from Five Years of Scrutiny. Organic Process Research & Development 2023, Article ASAP.